By reducing key markers of neuroinflammation (IL-1β, TNF-α), oxidative stress (MDA, iNOS), and neurodegeneration (Aβ42, tau, and p-tau181), PSO demonstrates a broad-spectrum therapeutic impact οn both a preclinical model and on patients with mild cognitive impairment. Here, MAPT is linked to Cognitive impairment.